Kite Pharma Announces Pricing of Follow-On Offering
10 déc. 2014 21h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Files Registration Statement for Proposed Follow-On Offering
26 nov. 2014 16h30 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
18 nov. 2014 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Investigational Cancer Immunotherapy
17 nov. 2014 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Reports Third Quarter 2014 Results
14 nov. 2014 15h20 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014
05 nov. 2014 08h00 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
13 oct. 2014 08h00 HE
|
Kite Pharma, Inc.
Phase 1 Clinical Trial Highlights:
14 of 20 pediatric or young adult patients (70%) with relapsed or refractory ALL experienced a complete response.
12 of the 20 patients (60%) achieved a...
Kite Pharma to Participate in Gene Therapy Panel at the BIO Investor Forum
03 oct. 2014 18h30 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26
16 sept. 2014 12h55 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
26 août 2014 07h30 HE
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...